ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

CDK6

cyclin dependent kinase 6 · also PLSTIRE · Cyclin dependent kinases

7 programs in company-led studies act on CDK6, from 7 companies: 2 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
abemaciclibruleEli Lillyinhibitorphase 44914 runningCDK4NCIt
palbociclibrulePfizerinhibitorphase 4364 runningCCND1, CDK4ChEMBL
trilaciclibrulePharmacosmosinhibitorphase 4143 runningCDK4ChEMBL
culmerciclibSino Biopharmaceuticalinhibitorphase 3115 runningCDK2, CDK4the company's pipeline
flonoltinibruleChengdu Zenitar Biomedical Technologyinhibitorphase 374 runningFLT3, JAK2the studies' text
narazaciclibruleHangzhou Hanx Biopharmaceuticalsinhibitorphase 243 runningCDK4, NUAK1NCIt
vustanaciclibRegor Pharmaceuticalsinhibitorphase 233 runningCDK2, CDK4a judged reading

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.